Angioedema Coexisting Chronic Spontaneous Urticaria Negatively Influences Patients' Sense of Coherence, What Results in Susceptibility to Anxiety Symptoms Occurrence

被引:3
|
作者
Badura-Brzoza, Karina [1 ]
Brzoza, Zenon [2 ]
机构
[1] Med Univ Silesia, Fac Med Sci Zabrze, Dept Psychiat Tarnowskie Gory, PL-42612 Tarnowskie Gory, Poland
[2] Univ Opole, Inst Med Sci, Dept Internal Dis, Div Allergol, Al W Witosa 26, PL-45401 Opole, Poland
关键词
sense of coherence; anxiety; urticaria; angioedema; QUALITY-OF-LIFE; DEPRESSION; ASTHMA;
D O I
10.3390/jcm10132852
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Angioedema coexisting chronic spontaneous urticaria (CSU) is proved to result in patient anxiety occurrence, but the mechanisms and susceptibility patterns are unknown. Sense of coherence (SOC) is one of methods of coping with stress and is defined as a person's general orientation toward life. We decided to assess SOC disturbances in CSU patients in the context of possible angioedema association. Methods: The study comprised 71 CSU subjects. To analyze disease activity, the Urticaria Activity Score seven-day assessment questionnaire (UAS7) was used. For anxiety assessment, the STAI questionnaire was used. The SOC-29 questionnaire, consisting of questions related to comprehensibility (SOC-C), manageability (SOC-M), and meaningfulness (SOC-Mf), was used to analyze SOC parameters (SOC-T). Results: In patients with coexisting angioedema, we observed statistically significantly lower values of SOC-Mf and SOC-T in comparison to the wheals only group. In the angioedema group, we noticed significant negative correlations between SOC-M and SOC-Mf, as well as SOC-T values and anxiety. In the wheals only group, we proved statistically significant correlations between SOC-Mf and SOC-T and anxiety assessed as a state. Conclusions: It is necessary to identify CSU patients manifesting angioedema as they are more likely to have impaired SOC. Lower SOC in this specific group of patients can be related to anxiety symptoms occurrence and should probably be an indication for psychological support.
引用
收藏
页数:5
相关论文
共 11 条
  • [1] Patients treated with ligelizumab achieve freedom fromsigns and symptoms of chronic spontaneous urticaria regardless of the angioedema status at baseline
    Sitz, Karl
    Soong, Weily
    Bernstein, Jonathan A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB90 - AB90
  • [2] Omalizumab retreatment of patients with chronic idiopathic urticaria / chronic spontaneous urticaria following return of symptoms: primary results of the optima study
    Sussman, G.
    Hebert, J.
    Gulliver, W.
    Lynde, C. W.
    Yang, W.
    Chambenoit, O.
    Vieria, A.
    Detakacsy, F.
    Rihakova, L.
    ALLERGY, 2017, 72 : 327 - 327
  • [3] Ligelizumab achieves sustained control of chronic spontaneous urticaria symptoms of hives, itch and angioedema: 1-year treatment results
    Bernstein, J. A.
    Baker, D.
    Maurer, M.
    Gimenez-Arnau, A. M.
    Sussman, G.
    Barve, A.
    Hua, E.
    Severin, T.
    Janocha, R.
    ALLERGY, 2019, 74 : 21 - 21
  • [4] Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE
    Buttgereit, Thomas
    Vera, Carolina
    Aulenbacher, Felix
    Church, Martin K.
    Hawro, Tomasz
    Asero, Riccardo
    Bauer, Andrea
    Bizjak, Mojca
    Bouillet, Laurence
    Dissemond, Joachim
    Fomina, Daria
    Gimenez-Arnau, Ana M.
    Grattan, Clive
    Gregoriou, Stamatios
    Kulthanan, Kanokvalai
    KasPerska-Zajac, Alicja
    Kocatuerk, Emek
    Makris, Michael
    Kolkhir, Pavel
    Weller, Karsten
    Magerl, Markus
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (11): : 3515 - +
  • [5] Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: results from the X-ACT study
    Weller, K.
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Maurer, M.
    ALLERGY, 2017, 72 : 96 - 96
  • [6] Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: Results from the X-ACT study
    Weller, Karsten
    Staubach, Petra
    Metz, Martin
    Chapman-Rothe, Nadine
    Sieder, Christian
    Brautigam, Matthias
    Maurer, Marcus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB209 - AB209
  • [7] UNDERSTANDING THE IMPACT OF CHRONIC SPONTANEOUS URTICARIA (CSU) AND WHAT IS MOST IMPORTANT TO PATIENTS - RESULTS FROM QUALITATIVE PATIENT INTERVIEWS
    Maurer, M.
    Balp, M. M.
    O'Donoghue, J.
    Danyliv, A.
    Christen, L.
    Smeets, S.
    Mueller, M.
    LopezOrtiz, D.
    Mckenna, S. J.
    De Ruijter, A.
    Freedle, K.
    Morrison, S.
    Winders, T.
    Bernstein, J. A.
    Gimenez-Arnau, A. M.
    VALUE IN HEALTH, 2022, 25 (01) : S244 - S244
  • [8] Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Canvin, J.
    Maurer, M.
    ALLERGY, 2016, 71 (08) : 1135 - 1144
  • [9] Improved reduction of symptoms by 20 versus 5 mg desloratadine in patients with chronic spontaneous urticaria: first results of a randomised, double-blind trial
    Weller, K.
    Ardelean, E.
    Martus, P.
    Zuberbier, T.
    Maurer, M.
    ALLERGY, 2010, 65 : 205 - 206
  • [10] Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial (vol 71, pg 1135, 2016)
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Brautigam, M.
    Canvin, J.
    Maurer, M.
    ALLERGY, 2017, 72 (09) : 1430 - 1430